|Publication number||US3249109 A|
|Publication date||3 May 1966|
|Filing date||1 Nov 1963|
|Priority date||1 Nov 1963|
|Publication number||US 3249109 A, US 3249109A, US-A-3249109, US3249109 A, US3249109A|
|Inventors||Maeth Harry, Pennings Ralph David|
|Original Assignee||Maeth Harry, Pennings Ralph David|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (9), Referenced by (132), Classifications (24)|
|External Links: USPTO, USPTO Assignment, Espacenet|
Ma 3, 1966 H. MAETH ETAL 3,249,109
TORI CAL DRESS ING Filed Nov. 1, 1963 HARRY MA ETH R. DAVID PENNINGS BY Vndrus 9f Star/ 52 A'f-ronwsvs INVENTORS United States Patent 3,249,109 TOPICAL DRESSING Harry Maeth, 101 Main, and Ralph David Pennings, 302 Main, both of Mosinee, Wis. Filed Nov. 1, 1963, Ser. No. 320,809 9 Claims. (Cl. 128-268) This invention relates to a pharmaceutical preparation and more particularly to a pharmaceutical preparation for topical application to mucous membranes.
It is often desired to apply a dressing to the mucous membranes of the body, such as the oral cavity. For example, it may be desired to apply a post-operative dressing following gum surgery, or to use a dressing for intraoral traumatic wounds. In the past, dressings to be used in the oral cavity were generally made of tinfoil and included a base plate material which required heat to adapt it to its position on the membrane. If the dessing included a medicament or therapeutic agent, leakage of the agent generally occurred and could not be controlled. This resulted in the incomplete application of the agent to the site of treatment and dispersion of the agent into the mouth and possible entry into the alimentary tract.
The present invention is directed to an adhesive dressing to be topically applied to the body and in particular to the mucous membranes, such as the oral cavity. More specifically, the dressing or pharmaceutical preparation includes a flexible adhesive base composed of hydrated gelatin and including a small amount of pectin. In addition, a medicament or therapeutic agent can be incorporated in the flexible base. The base material is applied to the membrane at the site of the treatment and will adhere to the moist membrane. To prevent loss of the medicament or therapeutic agent, a backing member is applied to the outer surface of the flexible base. The backing member may take the form of a generally inert fabric, such as glass fibers, muslin or the like.
The hydrated gelatin base, which serves as the vehicle for the medicament or therapeutic agent, is flexible and is very adhesive and will readily adhere to the surfaces of the oral cavity or other mucous membranes. The gelatin base will remain flexible for extended periods of time and will not crack or chip. Moreover, the base does not contain oils or essential oils which can be irritating or toxic to the patient.
The use of the fabric backing layer insures theproper dosage of the medicament or therapeutic agent and prevents the dispersion of the agent from the site of treatment, thereby preventing the dispersion of the agent into the mouth and possible entry into the alimentary tract.
The pharmaceutical preparation or dressing can be used as a post-operative dressing in gum surgery, as a dressing for intraoral traumatic wounds, for the management of soft tissue lesions in the mouth, and as an irradiation shield for the treatment of malignant conditions with X-ray. In addition, it can also be used for topical application to the skin for abrasions, burns, varicose ulcers, and the like.
Other objects and advantages will appear in the course of the following description.
The drawings illustrate the best mode presently contemplated of carrying out the invention.
In the drawings:
FIG. 1 is a perspective view of a dressing prepared in accordance with the invention;
I FIG. 2 is a modified form of the invention showing the dressing in the form of a roll; and
FIG. 3 is a second modified form of the invention showing the dress-ing in the form of a pre-cut strip.
3,249,109 Patented May 3 1966 FIG. 1 shows a dressing 1 to be used for topical applications and particularly to the mucous membranes of the body. The dressing has particular application to the mucous membranes of the oral cavity, but also includes other areas such as the vagina, rectum, etc.
The dressing 1 includes a flexible hydrated gelatin base 2 and a fabric backing member 3. The hydrated gelatin base 2 contains by weight, 10 to 40% gelatin, 5 to Water, 15 to 80% polyhydric alcohol and up to 15% pectin.
The preferred range of composition, in weight percent is as follows:
Percent Gelatin 1033 Water 50-85 Polyhydric alcohol 15-35 Pectin 1-4 The hydrated gelatin gives the base its consistency and bulk and serves as the vehicle for the incorporation of medicaments and therapeutic agents.
Pectin is a carbohydrate obtained from the dilute acid extract of the inner portion of the rind of citrus fruits or apple peel. Pectin consists chiefly of partially methoxylated polygalacturonic acids.
The pectin provides adhesive properties to the hydrated gelatin and enables the gelatin base to be readily applied to moist surfaces, such as the mucous membranes.
The polyhydric alcohol serves to prevent brittleness and retains the flexible characteristics of the material for extended periods. The polyhdric alcohol can be glycerin, polyoxyethylene, propylene glycol, sorbitol, ethylene glycol (when used externally), and the like.
It is also contemplated that the base 2 will include a pharmacologically active material such as a medicament or a therapeutic agent. More specifically, the pharmacologically active material may include enzymes such as hyaluronidase; vasoconstrictors such as epinephrine; bactericides; bacteristatics; antacids; anesthetics; corticosteroids; antibiotics; hemostats; fluorides such as sodium fluoride, stannous fluoride, calcium fluoride; astringents, hormones; vitamins; tissue growth promoters such as Peruvian balsam; deodorants such as charcoal, and chlorophyll, and the like. The pharmacologically active material is used in an amount up to 10% by weight of the composition with the particular amount depending on the activity of the material.
The backing member 3 is formed of an inert, non toxic fibrous material such as glass fiber, muslin and the like. The use of glass fiber cloth has proven particularly satisfactory as a reinforcement and as a dam to reduce the spreading of the pharmacologically active material bility and a marked resistance to steam, corrosive fumes and most acids. In addition, the glass fiber will not absorb water and can be readily sterilized and re-sterilized and withstands repeated folding and creasing.
The fabric backing member 3 serves as a barrier and assures that the proper dosage of the medicament or therapeutic agent is supplied to the site to be treated. The backing member 3 prevents the agent from being dispersed into the mouth and prevents the entry of the agent into the alimentary tract.
To prepare the dressing of the invention, the gelatin and a portion of the Water and glycerin are mixed at an elevated temperature of about C. to form a gelatin component. ing portion of the water and glycerin to form a pectin component which is then added to the heated gelatin component. In some cases it may be desirable to add a The pectin is then mixed with the remainsmall amount, in the range of 1 to 2% of the total composition weight, of alcohol, such as ethyl alcohol, to the pectin component. The alcohol provides a rapid hydration of the pectin and can be omitted, but, if omitted, increases the time required for preparation.
After adding the pectin component to the gelatin component, the medicament or therapeutic agent is added as a solution or suspension, depending upon the particular agent used. The entire composition is then agitated to thoroughly mix the components and is subsequently poured into the desired mold and cooled. The backing member 3 is then overlayed onto the base material.
Example 1 As a specific example of the preparation, 30 grams of gelatin, 30 cc. of distilled water and 30 cc. of glycerin were mixed together and heated to a temperature of 90 C. to melt the gelatin. After the gelatin was melted, the pectin component consisting of 5 cc. of ethyl alcohol, 40 cc. of distilled water, cc. of glycerin and 5 grams of pectin was added to the liquid gelatin component and mixed therewith.
After adding the pectin component, 8 grams of Benzocaine and 40 cc. of alcohol, and 0.5 gram of Triburon (triclobisonium chloride) in 10 cc. of distilled water were added to the composition. After mixing in the Benzocaine and Triburon, the composition was poured into a mold and cooled. A glass fiber backing sheet was then overlayed over the composition and pressed firmly therein.
The resulting dressing was flexible and very adhesive and could readily be applied to mucous membranes.
Example 2 Three grams of pectin, 10 cc. of ethyl alcohol, 80 cc. of distilled water and 40 cc. of glycerin were mixed together. Forty grams of gelatin were added to this mixture and the entire composition heated to a temperature of 90 to 100 C. to melt the gelatin. Subsequently, 0.25
gram of Triburon in 17 cc. of glycerin and 20 cc. of distilled water were added to the gelatin-pectin composition. The resulting composition was then poured onto a suitable mold and cooled.
FIG. 2 shows a modified form of the invention in which the dressing is in strip form. In this embodiment the dressing includes a hydrated gelatin base 4 similar in composition to gelatin base 2 of the first embodiment. A fabric backing member 5 is applied to one surface of the base 4 and the backing member 5 is similar in structure and function to the backing member 3 of the first embodiment. In addition, a protective strip of material, such as waxed paper or other material, is applied to the outer surface of the barrier and serves to prevent the strip from sticking to itself when it is wound in spiral form.
The strip shown in FIG. 2 can be unwound as desired and cut to any length, depending on the nature of the site to be treated.
FIG. 3 shows a second modified form of the invention in which the dressing is in the form of a pre-cut strip. In this embodiment, the hydrated gelatin base 7, similar to base 2 of the first embodiment, is applied to an adhesive backing member 8. In this embodiment, a protective strip of material is applied to the adhesive surface of the strip 8 and can be removed immediately prior to application of the strip to the body surface.
The dressing of the invention is used for topical application, and particularly to the moist mucous membranes. For example, the dressing can be used as a post-operative dressing following surgery, as a dressing for traumatic wounds, 'as a dressing for soft tissue lesions and it also may be employed as an irradiation shield for the treatment of malignant conditions with X-ray. In this lattercase, a radiation barrier, such as powdered lead or barium sulphate, can be incorporated in the flexible base 2 in an amount of about 10 to 30% by weight of the base. The lead or barium sulphate is radiopaque material and serves as an irradiation shield to protect structures such as teeth and soft tissues from the radiation. This type of barrier is considerably more flexible and pliable than sheet lead for intraoral use, and being a lightweight material, is exceedingly more comfortable to the patient.
The dressing of the invention is flexible and will tightly adhere to moist membrane surfaces. If the dressing is to be applied to the external body tissues, it may be necessary to moisten the tissue before application.
It is contemplated that pharmacologically active materials can be incorporated in the hydrated gelatin base and the backing member serves to concentrate the activity of the material at the site of treatment and prevents the pharmacologically active material from dispersing outwardly into the mouth or other regions of the body.
Various modes of carrying out the invention are contemplated as being within the scope of the following claims particularly pointing out and distinctly claiming the subject matter which is regarded as the invention.
1. A pressure sensitive dressing for topical application, comprising a solid, flexible hydrated gelatin base capable of maintaining its shape and containing a suflicient amount of pectin to provide initial adhesiveness for application to moist tissue and containing a sufiicient amount of a polyhydric alcohol to maintain flexibility for extended periods, and a generally inert non-toxic fibrous backing member disposed on one surface of said base and serving to prevent the outward dispersion of materials from the base.
2. A dressing for topical applications, comprising a solid, flexible, adhesive, film-like, hydrated gelatin base consisting essentially by weight of 10 to 40% gelatin, 5 to 85% water, 15 to of a polyhydric alcohol, and up to 15% pectin, and a fibrous backing member applied to one surface of the base, said backing member reinforcing the base and serving to prevent the outward dispersion of materials from the base.
3. The structure of claim 2, in which the hydrated gelatin base contains up to 10% by weight of a pharmacologically active material, said backing member serving to concentr-ate the pharmacologically active material at the site of treatment and preventing the outward dispersion of said material.
4. The structure of claim 2, in which the polyhydric alcohol is selected from the group consisting of glycerin, polyoxyethylene, propylene glycol, ethylene glycol, and sorbitol.
5. The structure of claim 3, in which the backing member is composed of glass fiber fabric.
6. A pressure sensitive dressing for topical applications, comprising a nonflow-able flexible, adhesive, hydrated gelatin sheet consisting essentially by weight of 10 to 33% gelatin, 50 to water, 1 to 4% pectin, 15 to 35% glycerin, and up to 10% of a pharmacologically active material, and a fabric backing member applied to one surface of the hydrated gelatin sheet, said backing member serving to concentrate the pharmacologically active material at the site of treatment and preventing the outward dispersion of said material.
7. The structure of claim 6 in which the hydrated gel-atin sheet also includes from 1 to 2% by weight of alcohol.
8. A dressing for topical applications, comprising a flexible, adhesive, hydrated gelatin base consisting essentially by weight of 10 to 40% gelatin, 5 to 85% Water, 15 to 80% of a polyhydric alcohol, up to 15% pectin and from 10 to 30% by weight of a material selected from the group consisting of lead and barium sulfate, and a fibrous backing member applied to one surface of the base, said backing member reinforcing the base and serving to prevent the outward dispersion of the material from the base, said material serving as a radiation shield to protect portions of the body from radiation.
9. A pressure sensitive article, comprising a flexible, adhesive, hydrated gelatin base containing up to 30% by weight of a radiopaque material, and a fabric backing member applied to one surface of the hydrated gelatin base, said backing member serving to concentrate the radiopaque material at the site of treatment and prevent the outward dispersion of said materiaL-said mtaerial serving as a radiation shield to protect portions of the article from radiation.
References Cited by the Examiner UNITED STATES PATENTS 307,537 11/1884 'Foulks 167 84 335,799 2/ 1886 Baby. 2,115,237 4/1938 Scholl 128268 X 6 Donaldson 1'28156 Shrontz 128-268 Reese.
Hirsch 106-125 Steinhardt 32--2 X FOREIGN PATENTS Germany.
OTHER REFERENCES Macleods Physiology in Modern Medicine, Bard, 8th edition, 1938.
ROBERT E. MORGAN, Primary Examiner.
15 RICHARD A. GAUDET, Examiner.
C. F. ROSENBAUM, Assistant Examiner.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US307537 *||4 Nov 1884||Dental capsicum-bag|
|US335799 *||26 Oct 1885||9 Feb 1886||Itnesses|
|US2115237 *||11 May 1936||26 Apr 1938||Scholl William M||Medicated button|
|US2450083 *||7 Feb 1944||28 Sep 1948||Munising Paper Company||Treated paper liner for adhesive rolls|
|US2501544 *||23 Oct 1946||21 Mar 1950||Shellmar Products Corp||Therapeutic product|
|US2583341 *||21 Mar 1950||22 Jan 1952||Reese John D||Skin graft receiving member|
|US2950980 *||10 Sep 1958||30 Aug 1960||Arthur Hirsch||Adhesive compositions|
|US3029187 *||20 Feb 1958||10 Apr 1962||Amos Steinhardt||Gelating adhesive pharmaceutical preparations|
|DE1074979B *||Title not available|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3329145 *||12 Feb 1965||4 Jul 1967||Johnson & Johnson||Sanitary napkin having control element with gel-forming material|
|US3339546 *||13 Dec 1963||5 Sep 1967||Squibb & Sons Inc||Bandage for adhering to moist surfaces|
|US3444858 *||11 May 1966||20 May 1969||Higham S Russell||Method and means for administering drugs|
|US3598123 *||1 Apr 1969||10 Aug 1971||Alza Corp||Bandage for administering drugs|
|US3688406 *||7 Aug 1970||5 Sep 1972||Frank W Hindsley||Apparatus for and method of applying decay retardant compositions to teeth|
|US3696811 *||17 Jun 1971||10 Oct 1972||Squibb & Sons Inc||Periodontal bandage and backing therefor|
|US3769071 *||4 Jun 1971||30 Oct 1973||Minnesota Mining & Mfg||Pressure sensitive adhesive tape comprising 5-fluorouracil|
|US3960150 *||15 Sep 1975||1 Jun 1976||Alza Corporation||Bioerodible ocular device|
|US3981303 *||31 Jul 1975||21 Sep 1976||Alza Corporation||Bioerodible ocular device|
|US3986510 *||1 Aug 1975||19 Oct 1976||Alza Corporation||Bioerodible ocular device|
|US3993071 *||24 Jul 1975||23 Nov 1976||Alza Corporation||Bioerodible ocular device|
|US3993073 *||3 Mar 1975||23 Nov 1976||Alza Corporation||Novel drug delivery device|
|US3996934 *||9 Aug 1971||14 Dec 1976||Alza Corporation||Medical bandage|
|US3998215 *||23 Apr 1971||21 Dec 1976||Minnesota Mining And Manufacturing Company||Bio-medical electrode conductive gel pads|
|US4022203 *||22 Jan 1976||10 May 1977||Win Ackley||Treated patch for minor cuts|
|US4062361 *||7 Jul 1975||13 Dec 1977||Coloplast International A/S||Bilaminar ostomy sealing disc|
|US4239488 *||15 Jun 1979||16 Dec 1980||Sempler Vance A||Encapsulated denture adhesive and method of use|
|US4253460 *||27 Jul 1979||3 Mar 1981||E. R. Squibb & Sons, Inc.||Ostomy adhesive|
|US4265233 *||6 Apr 1979||5 May 1981||Unitika Ltd.||Material for wound healing|
|US4292299 *||7 Jul 1980||29 Sep 1981||Teijin Limited||Slow-releasing medical preparation to be administered by adhering to a wet mucous surface|
|US4306551 *||28 Jul 1980||22 Dec 1981||Lectec Corporation||Sterile improved bandage and sealant|
|US4307717 *||28 Jul 1980||29 Dec 1981||Lectec Corporation||Sterile improved bandage containing a medicament|
|US4321252 *||17 Dec 1980||23 Mar 1982||Key Pharmaceuticals, Inc.||Polymeric diffusion matrix containing ester derivatives of estradiol|
|US4329333 *||24 Nov 1980||11 May 1982||Arthur Barr||Method for the oral treatment of dogs and other animals|
|US4460562 *||30 Mar 1983||17 Jul 1984||Key Pharmaceuticals, Inc.||Polymeric diffusion matrix containing propranolol|
|US4470962 *||28 Apr 1981||11 Sep 1984||Key Pharmaceuticals, Inc.||Polymeric diffusion matrix|
|US4492685 *||30 Jan 1984||8 Jan 1985||Key Pharmaceuticals, Inc.||Protective skin matrix|
|US4631227 *||5 Dec 1983||23 Dec 1986||Kenji Nakamura||Toilet article|
|US4655211 *||8 Aug 1985||7 Apr 1987||Unitika Ltd.||Hemostatic agent|
|US4695465 *||5 Apr 1985||22 Sep 1987||Takeda Chemical Industry, Ltd.||Soft patch|
|US4728323 *||24 Jul 1986||1 Mar 1988||Minnesota Mining And Manufacturing Company||Antimicrobial wound dressings|
|US4877618 *||18 Mar 1988||31 Oct 1989||Reed Jr Fred D||Transdermal drug delivery device|
|US4906475 *||16 Feb 1988||6 Mar 1990||Paco Pharmaceutical Services||Estradiol transdermal delivery system|
|US4984570 *||14 Sep 1989||15 Jan 1991||Karl Otto Braun Kg||Knitted hydrophobic web wound dressing|
|US4991574 *||15 Aug 1990||12 Feb 1991||Dow Corning Corporation||Surgical dressing|
|US5096715 *||20 Nov 1989||17 Mar 1992||Alko Ltd.||Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist|
|US5207652 *||23 Oct 1991||4 May 1993||Bioderm||Medical apparatus fixation and infection control device|
|US5234957 *||23 Dec 1991||10 Aug 1993||Noven Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5332576 *||21 May 1993||26 Jul 1994||Noven Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5336501 *||29 Apr 1992||9 Aug 1994||Lohmann Gmbh & Co. Kg||Cross-linked hydrogels and their use as wound dressings|
|US5437621 *||12 Jan 1993||1 Aug 1995||Marmon Holdings, Inc.||Medical dressing of a multilayered material|
|US5446070 *||27 Aug 1993||29 Aug 1995||Nover Pharmaceuticals, Inc.||Compositions and methods for topical administration of pharmaceutically active agents|
|US5480377 *||28 Feb 1994||2 Jan 1996||New Dimensions In Medicine, Inc.||Wound dressing having a roll configuration|
|US5536263 *||30 Mar 1994||16 Jul 1996||Lectec Corporation||Non-occulusive adhesive patch for applying medication to the skin|
|US5741510 *||8 Apr 1996||21 Apr 1998||Lectec Corporation||Adhesive patch for applying analgesic medication to the skin|
|US5829442 *||12 Jun 1996||3 Nov 1998||Medical Concepts Development, Inc.||Antimicrobial containing solventless hot melt adhesive composition|
|US6016862 *||10 Mar 1999||25 Jan 2000||Hormel Foods Corporation||Collagen or gelatin crumble composition and uses|
|US6090915 *||18 Oct 1996||18 Jul 2000||Hormel Foods Corporation||Collagen or gelatin crumble composition and uses|
|US6096333 *||8 Oct 1997||1 Aug 2000||Lectec Corporation||Method of forming adhesive patch for applying medication to the skin|
|US6096334 *||14 Dec 1998||1 Aug 2000||Lectec Corporation||Adhesive patch for applying medication to the skin and method|
|US6469227||12 May 2000||22 Oct 2002||Lectec Corporation||Antipruritic patch|
|US6607746||24 Jul 2002||19 Aug 2003||Medical Concepts Development, Inc.||Antimicrobial containing solventless hot melt adhesive composition|
|US6664309||7 Dec 2000||16 Dec 2003||Bostik Findley, Inc.||Antimicrobial hot melt adhesive|
|US7087269||22 Jun 2001||8 Aug 2006||Lg Chemical Co., Ltd.||Multi-component composite membrane and method for preparing the same|
|US7157614||21 Dec 2001||2 Jan 2007||Fountainhead, Llc||Treatment devices providing targeted antimicrobial action|
|US7357891||30 Jan 2004||15 Apr 2008||Monosol Rx, Llc||Process for making an ingestible film|
|US7425292||14 Feb 2002||16 Sep 2008||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US7666337||28 May 2004||23 Feb 2010||Monosol Rx, Llc||Polyethylene oxide-based films and drug delivery systems made therefrom|
|US7824588||14 Apr 2008||2 Nov 2010||Monosol Rx, Llc||Method of making self-supporting therapeutic active-containing film|
|US7910641||14 Dec 2006||22 Mar 2011||Monosol Rx, Llc||PH modulated films for delivery of actives|
|US7972618||20 Sep 2007||5 Jul 2011||Monosol Rx, Llc||Edible water-soluble film containing a foam reducing flavoring agent|
|US8017150||22 Apr 2008||13 Sep 2011||Monosol Rx, Llc||Polyethylene oxide-based films and drug delivery systems made therefrom|
|US8475832||7 Aug 2009||2 Jul 2013||Rb Pharmaceuticals Limited||Sublingual and buccal film compositions|
|US8603514||10 Jul 2007||10 Dec 2013||Monosol Rx, Llc||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|
|US8614179||17 Jul 2009||24 Dec 2013||E-Therapeutics Plc||Antibacterial combination therapy for the treatment of gram positive bacterial infections|
|US8652378||29 Mar 2013||18 Feb 2014||Monosol Rx Llc||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|
|US8663687||13 May 2010||4 Mar 2014||Monosol Rx, Llc||Film compositions for delivery of actives|
|US8685437||26 Mar 2009||1 Apr 2014||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US8765167||8 Sep 2006||1 Jul 2014||Monosol Rx, Llc||Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions|
|US8900497||23 Aug 2013||2 Dec 2014||Monosol Rx, Llc||Process for making a film having a substantially uniform distribution of components|
|US8900498||23 Aug 2013||2 Dec 2014||Monosol Rx, Llc||Process for manufacturing a resulting multi-layer pharmaceutical film|
|US8906277||23 Aug 2013||9 Dec 2014||Monosol Rx, Llc||Process for manufacturing a resulting pharmaceutical film|
|US8974826||10 Jun 2011||10 Mar 2015||Monosol Rx, Llc||Nanoparticle film delivery systems|
|US9108340||23 Aug 2013||18 Aug 2015||Monosol Rx, Llc||Process for manufacturing a resulting multi-layer pharmaceutical film|
|US9248050||11 Oct 2012||2 Feb 2016||Roar Consultants||Wound dressing garment|
|US20030107149 *||14 Feb 2002||12 Jun 2003||International Fluidics.||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20040234605 *||19 Nov 2003||25 Nov 2004||Cox David D.||Antimicrobial adhesive system|
|US20040258738 *||8 Jul 2004||23 Dec 2004||Kania Bruce G.||Treatment devices providing targeted antimicrobial action|
|US20040258896 *||30 Jan 2004||23 Dec 2004||Monosolrx Llc.||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20050184427 *||29 Mar 2005||25 Aug 2005||Monosolrx, Llc.||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20060039958 *||28 Sep 2005||23 Feb 2006||Monosolrx, Llc.||Multi-layer films having uniform content|
|US20060147493 *||22 Jul 2003||6 Jul 2006||Yang Robert K||Packaging and dispensing of rapid dissolve dosage form|
|US20070069416 *||22 Jun 2006||29 Mar 2007||Monosolrx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20070122455 *||8 Sep 2006||31 May 2007||Monosolrx, Llc.||Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions|
|US20070149731 *||14 Dec 2006||28 Jun 2007||Monosolrx, Llc.||PH modulated films for delivery of actives|
|US20070154527 *||5 Dec 2006||5 Jul 2007||Monosoirx, Llc||Topical film compositions for delivery of actives|
|US20070172515 *||19 Jan 2007||26 Jul 2007||Monosolrx, Llc||Film bandage for mucosal administration of actives|
|US20070190157 *||19 Jan 2007||16 Aug 2007||Monosoirx, Llc.||Film lined packaging and method of making same|
|US20070281003 *||13 Feb 2007||6 Dec 2007||Fuisz Richard C||Polymer-Based Films and Drug Delivery Systems Made Therefrom|
|US20080044454 *||10 Jul 2007||21 Feb 2008||Monosolrx Llc||Uniform films for rapid dissolve dosage form incorporating taste-masking compositions|
|US20080075825 *||20 Sep 2007||27 Mar 2008||Fuisz Richard C||Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent|
|US20080078413 *||22 May 2007||3 Apr 2008||Padget David B||Surgical drape|
|US20080081071 *||28 Sep 2007||3 Apr 2008||Pradeep Sanghvi||Film Embedded Packaging and Method of Making Same|
|US20080220067 *||7 Jan 2008||11 Sep 2008||Cox David D||Antimicrobial adhesive system|
|US20080260805 *||14 Apr 2008||23 Oct 2008||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20080260809 *||22 Apr 2008||23 Oct 2008||Monosol Rx, Llc||Polyethylene oxide-based films and drug delivery systems made therefrom|
|US20090005443 *||20 Jun 2008||1 Jan 2009||Malcolm Philip Young||Treatment of Depression|
|US20090181069 *||26 Mar 2009||16 Jul 2009||Monosol Rx, Llc||Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom|
|US20100021526 *||7 Oct 2009||28 Jan 2010||Monosol Rx, Llc||Ph modulated films for delivery of actives|
|US20100227937 *||26 Feb 2010||9 Sep 2010||Cox David D||Antimicrobial adhesive system|
|US20110020217 *||10 Oct 2008||27 Jan 2011||E-Therapeutics Plc||Treatment of melanoma|
|US20110033376 *||4 Jul 2008||10 Feb 2011||Malcolm Philip Young||Treatment of Melanoma|
|US20110033541 *||7 Aug 2009||10 Feb 2011||Monosol Rx, Llc||Sublingual and buccal film compositions|
|US20110033542 *||7 Aug 2009||10 Feb 2011||Monosol Rx, Llc||Sublingual and buccal film compositions|
|US20110039906 *||18 Jul 2008||17 Feb 2011||E-Therapeutics Plc||Antibacterial combination therapy|
|US20110212173 *||17 Jun 2009||1 Sep 2011||e-Therapeutics Ple||Controlled Release Treatment of Depression|
|EP0044624A1 *||23 Jun 1981||27 Jan 1982||E.R. Squibb & Sons, Inc.||Lyophilized hydrocolloid foam|
|EP0159168A2 *||4 Apr 1985||23 Oct 1985||Takeda Chemical Industries, Ltd.||Soft patch drug preparation|
|EP0159168A3 *||4 Apr 1985||8 Jan 1986||Takeda Chemical Industries, Ltd.||Soft patch drug preparation|
|EP0161681A2 *||15 May 1985||21 Nov 1985||Mitsubishi Acetate Co., Ltd.||Gel plate and process for preparing same|
|EP0161681A3 *||15 May 1985||29 Apr 1987||Mitsubishi Acetate Co., Ltd.||Gel plate and process for preparing same|
|EP0167263A1 *||28 May 1985||8 Jan 1986||Matrix Pharmaceutical Inc.||Drug-containing matrices for introduction into cellular lesion areas|
|EP0177920A3 *||7 Oct 1985||3 Jun 1987||Teijin Limited||Pharmaceutical composition for external use containing active type vitam d3|
|EP0232580A2 *||21 Aug 1986||19 Aug 1987||Alza Corporation||Transdermal system II|
|EP0232580A3 *||21 Aug 1986||21 Jun 1989||Alza Corporation||Transdermal system ii|
|EP0297828A1 *||28 Jun 1988||4 Jan 1989||The Kendall Company||Novel medicated dressings|
|EP0438749A1 *||20 Dec 1990||31 Jul 1991||Beiersdorf Aktiengesellschaft||Self-adhesive mass from gelatine|
|EP0666081A1 *||20 Jan 1995||9 Aug 1995||Bristol-Myers Squibb Company||Wound dressing|
|EP0852148A1||7 Jan 1997||8 Jul 1998||Israel Fiber Institute||Products having anti-microbial activity|
|EP2014282A2||20 Jun 2008||14 Jan 2009||E-Therapeutics plc||Treatment of depression|
|EP2508231A2||15 Nov 2007||10 Oct 2012||E-Therapeutics Plc||Imidazoles for treating multi-drug resistant bacterial infections|
|EP2529733A1||18 Jul 2008||5 Dec 2012||E-Therapeutics Plc||Antibacterial combination therapy|
|EP2529737A1||18 Jul 2008||5 Dec 2012||E-Therapeutics plc||Antibacterial combination therapy|
|WO1993007928A1 *||23 Oct 1992||29 Apr 1993||Bioderm, Inc.||Medical apparatus fixation and infection control device|
|WO2009013480A2||18 Jul 2008||29 Jan 2009||E-Therapeutics Plc||Antibacterial combination therapy|
|WO2011030106A1||10 Sep 2010||17 Mar 2011||E-Therapeutics Plc||Cancer cell apoptosis|
|WO2012046006A2||7 Oct 2011||12 Apr 2012||University Of Dundee||Cancer targets|
|WO2012104589A1||2 Feb 2012||9 Aug 2012||University Of Edinburgh||Weight related disorders|
|WO2013160645A1||26 Apr 2013||31 Oct 2013||E-Therapeutics Plc||Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg|
|WO2013164561A1||3 May 2013||7 Nov 2013||E-Therapeutics Plc||Tramadol for treating depression|
|WO2015067746A1||7 Nov 2014||14 May 2015||Bsn Medical Gmbh||Medical dressing|
|WO2017068349A1||20 Oct 2016||27 Apr 2017||E-Therapeutics Plc||Cannabinoid for use in immunotherapy|
|U.S. Classification||604/304, 602/49, 433/180, 602/50|
|International Classification||A61K9/00, A61F13/00, A61F13/15, A61L15/58, A61L15/44|
|Cooperative Classification||A61F2013/00659, A61K9/006, A61L15/44, A61F2013/00472, A61F2013/53445, A61F13/122, A61L15/585, A61F13/0236, A61F13/8405, A61L2300/00, A61F13/00063|
|European Classification||A61L15/58M, A61K9/00M18D, A61L15/44, A61F13/00|